Genetic Testing

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApplied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

STONY BROOK, NY / ACCESSWIRE / January 31, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in…

1 year ago
Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal TestingBionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome mapping (OGM) that…

1 year ago
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research ApplicationsBionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual…

1 year ago
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision GenomicsMyriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and…

1 year ago
TOUCHBBCA Joins the Carebox Connect NetworkTOUCHBBCA Joins the Carebox Connect Network

TOUCHBBCA Joins the Carebox Connect Network

When We Tri(al) by TOUCH, The Black Breast Cancer Alliance has partnered with Carebox to provide Breasties, caregivers, and the…

1 year ago
Mainz Biomed Provides Year-End Corporate Review 2023Mainz Biomed Provides Year-End Corporate Review 2023

Mainz Biomed Provides Year-End Corporate Review 2023

European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced…

1 year ago
International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy ApplicationsInternational Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications

International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications

Framework was co-authored by an international consortium made up of 18 cancer researchers Publication includes researchers’ recommendations for laboratories planning…

1 year ago
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial GuidanceMyriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

Scott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler…

1 year ago
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing WorkflowApplied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow

Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow

- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with…

1 year ago